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Mechanisms and Therapeutic Implication s
of Neuroleptic Atypicality
Daniel C. Javitt, M.D .
PRECIS

Neuroleptics have proven effective for the overall treatment of schizophrenia . The neu roleptic therapy of schizophrenia, however, has been limited b y
tardive dyskinesia and by the relative inability of neuroleptics to ameliorate th e
negative symptoms of schizophrenia. Intensive research has been conducted to
identify atypical neuroleptics which would not cause TO and which would ha ve
relatively greater efficacy in treating negative symptoms. Based upon animal
models of T D and negative symptoms, four neuroleptics have been identified
which may have these properties: c1ozapine, thioridazine, sulpiride, and molindone. Clinical studies of TD suggest that these four potentially atypical agents
may have lower dyskinetic potential than typica l neuroleptics. Additionall y,
clinical studies of negative symptoms suggest that molindone and sulpiride, bu t
not clozapine or thioridazine may preferentially treat depressive-like negati ve
schizophrenic symptomatology. The atypical effects of c1ozapine, thioridazine,
sulpiride and mo lindone, suggest that they may have a distinct place in th e
pharmacotherapy of schizophrenia.
INTRODUCTION

Since their d iscovery in the mid-1950s, neuroleptic drugs have proven to
be safe and effective treatments for schizophrenia . Schizophrenic subjects
treated with neuroleptics have been shown to have improved overall functionin g
and a decreased need for ho sp italizat io n versus non-treated controls. The
pharmacotherapy of schizophrenia with neuroleptics, however, has proven to be
limited by at least two factors. First, neuroleptics increase the rate at which
schizophrenic patients develop the long-term potentially irreversible and incapacitating movement disorder, tardive dyskinesia (TO). Second, neuroleptics
have proven relative ly ine ffective in treating the negative symptoms of schizophrenia (e.g. blunted affect, poverty of speech and of ideation) (1,2) and ma y
induce akinetic symptoms which closely resemble the negative schizophrenic
sym ptoms (3,4). Intensive research has been conducted over the past three
decades on bo th a basic scie nce and a clinical leve l to determine whether or not
these two lim ita tio ns are inevitable concomitants of neuroleptic therapy. Basic
studies using anima l models of TO and negative symptoms now suggest that
several agents do behave differently from trad itiona l neuroleptics (e.g. chlorprom azin e , hal operidol) an d may indeed possess atypica l clinical properties
3
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including a relatively decreased dyskinetogenic potential and/ or a r elativel y
increased efficacy in treating negative symptoms. Four such potentially atyp ica l
agents have been identified. Clozapine, a compound of th e diben zodiazepine
class, has been the best studied and is considered th e prototype atypical
neuroleptic. Long-term clinical studies have suggested that clozapine has lo w to
absent dyskinetogenic potential. Clozapine, however , remains available in th is
country only on an experimental basis because of associated agranulocyto sis.
Thioridazine, a widely used neuroleptic of the piperidine phenothiazine clas s,
appears to have c1ozapine-like effects in basic models of TD although to a more
limited extent. Detailed clinical studies have not been conducted th at woul d
allow a determination of the dyskinetogenic potential of thioridazine. Cases of
TD presumably related to thioridazine treatment have been reported and th e
possible decreased dyskinetogenic potential of thioridazine has been much
debated (5,6). Sulpiride, a substituted benzamide, and molindone, an indol ic
derivative, are other neuroleptics with novel chemical structures. These agents,
at least in some dose ranges, behave similarly to clozapine in basic models of TD.
While definitive clinical studies have yet to be performed for th ese ag ents,
studies using masking paradigms suggest that these agents also may ha ve
decreased dyskinetogenic potential compared with traditional neurolept ics.
Sulpiride and molindone behave differently from traditional neuroleptics in
animal models of negative symptoms as well, suggesting that th ey may also have
improved efficacy in treating negative symptoms.
BASIC STUDIES

The role of dopaminergic hyperactivity in schizophreni c pathoph ysio lo gy
has now been well established. Agents which increase brain dopaminergic
transmission worsen overall schizophrenic symptomatology. The poten cy wit h
which neuroleptic agents ameliorate schizophrenic symptoms correl at es wit h
their potency in blocking dopaminergic transmission at D 2 type dopami ne
receptors (7,8). Less well established, however, is the role of the various brain
dopaminergic systems in contributing to schizophrenic pathoph ysiology and t he
clinical response to neuroleptics. Three separate dopamin ergic systems ha ve
been identified in forebrain. Two of these, the mesocortical and mesolimbic
systems arise from the midbrain ventral tegmental area (area Al 0) and innervate
the neocortex (e.g. frontal cortex, cingulate cortex) and limbic system (e.g .
nucleus accumbens) respectively. The third arises from the substantia nigra
(area A9) and innervates the neostriatum. The me socortical and mesolimbic
systems are thought to subserve co gn it io n and affective regulation whil e th e
nigrostriatal system , which has been implicated in th e pathoph ysiol ogy of
Parkinson's disease (9) and Huntington's chorea (10), is thought to be inv ol ved
mainl y with regulation of brain motoric systems. The th erapeutic ac tions of
neuroleptics and their behavioral side effects ma y result primarily from th e ir
actions in the mesolimbic and mesocortical systems while the d yskinet oge n ic
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effects of neuroleptics are likel y to be mediated b y th ei r actions on the
nigrostriatal syste m (7 ,8). As a result, agents whi ch se lec tive ly spare th e nigrostriatal system should have a relativel y decreased risk of inducin g T D. Several
model systems have been used in an attempt to measure th e effec ts of neuro leptics on th e mesocortical and mesolimbic systems versus th eir effects on the
nigrostriatal system. Three of th ese paradigms in particul ar have gained
widespread acceptance (Table I). Studies using th ese paradi gms suggest that the
proposed atypica l agents c1ozapine, thioridazin e , sulp ir ide, an d molindone
induce less inhibition o f nigrostriatal dopamin ergic transm ission tha n traditional agen ts. Th ese agents, therefore, might have a relati vel y d ecreased risk for
inducing motoric side e ffects and , in particular, T D.
Behavioral Supersensitivity

The first model of TD is bas ed upon th e observation tha t in rats the
dopamin ergic agent amphetamin e produces a characteristi c syndro me of stereotypies and h yperactivity. Amphetamine-induced ste re o typ ies have been shown
to be mediated b y th e nigrostriatal syst em whil e amph etamin e-induced hyperactivity is mediated by th e mesolimbic syst em ( 1 1, 12). Typ ica l neu rolept ic agents
TABLE 1.
Summary of Animal Models for Tardive Dyskinesia
Paradigm
Behavioral
supe rsens itivity

T ypical Neuroleptics
ac u te :

ch ro n ic:

! a m pe ta m ine

! amphet amine induced

!

hyperact ivity
N.C . a m p he ta m ine induced stereotypy

ch ro n ic:

Depolarization
ina ctivation

acute:

i a m p hetamine

ind uced
stereo typy
.C. a m p he ta m ine induced stereotypy

stereotyp y
a m p heta m ine induced
ste reotypy

i receptor density - nui

ch ro n ic:

induced
hyperactivity
amph et amine induced
ste reotypy

i amphet amine ind uced
i

Re ceptor
supersensitivity

At ypical Ne uroleptics

cleus accumbens
receptor density - str iatum

i firing rate - A9
i firing rate - Al 0
! firing rat e - A9
! firing rate - Al 0

i

recepto r d en sit y - nucleu s accumben s
N .C . receptor density
striatum

N .C . o r ! firing rat e - A9
firin g rat e - A l 0

i

N. C. fir ing rat e - A9

! fir in g r at e - Al 0

Effects of acute a nd chronic treatments with t ypical a nd a typ ica l neuroleptics on
amphetamine-induced hyperactivity and stereotypi es, on dopamine recepto r den sity in
nucleus accumbens and striatum and o n the firing rate of neurons in A9 a nd Al 0
midbrain dopaminergic nuclei . N.C. indicates no cha nge.
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acutely block both amphetamine-induced ste reo ty p ies and h yperact ivity suggesting that they induce a net dopaminergic block ade in both th e n igrostriatal
and the mesolimbic systems. The prototypical atypi cal ag ent c1ozapine, conversely, inhibits only amphetamine-induced hyperactivity whil e parado xically
enhancing amphetamine-induced stereotypies (13-17). Clo zapine , th ere fore ,
appears to block dopaminergic transmission onl y in th e mesolimbic system whi le
sparing or possibly enhancing nigrostriatal dopamin ergic transmi ssio n . T hi oridazine (16-18), su lp ir ide (13 ,16,17,19-21 ) and molindone (22) also pote ntia te
amphetamine-induced stereotypies suggesting that th ese agents a lso spare
nigrostriatal system functioning.
Following chronic treatment with typical neuroleptic agents, rat s show a n
increased sensitivity for developing amphetamine- induced ste reotypies and
h yperactivity. This increased sensitivity is thought to result fr om a co m pensatory supersensitivity of nigrostriatal and mesolimbic dopamin ergic receptors
following prolonged blockade. In contrast to typical agents, clo zap ine h as been
shown to induce supersensitivity only o f a m p heta m ine-ind uced h yperact ivity
and not of amphetamine-induced ste ro ty p ies (14 ,1 5) suggest ing that it d oes not
induce long-term changes in nigrostriatal system functioning . T h ioridazi ne (23),
sulpiride (19) and molindone (24,25) either do not induce supe rsens it ivity to
amphetamine-induced stereotypies in rats following chronic treatment o r d o so
with considerabl y less potency than equivalent dosages o f traditional agents.
While a relationship between behavio ral supersens it ivity to a m p heta mi ne and
TD ha s ye t to be demonstrated, th e relative ability of th ese proposed atypical
agents to spare the nigrostriatal syst em suggests that th ese agen ts ma y be less
likely than typical agents to induce long-term c ha nge s in th e nigro striaral
system .
Receptor Supersensitivity

In order to investigate whether dopamine receptor superse ns itiv ity u nde rlies the neuroleptic-induced behavioral superse nsitivity, dopamine rece p to rs in
the striatum and nucl eus accumbens have been stud ied d ir ectl y usin g radiolabelled agents which bind specificall y to D 2-t ype dopamine receptors (e.g.
[3H ]spiperone). Traditional neuroleptics have been sh o wn to induce a n increase
in the number of D 2 receptors in the striatum following days to weeks of
continuous treatment. By contrast clo zap ine ( 14 , 15 ,2 6), su lp ir id e (26, 2 7) and
molindone (24) do not induce supersensitivity of striatal D2 receptors, suggesting
again that these agents affect nigrostriatal dopaminergic transmi ssion to a lesse r
extent than traditional agents do .
Shortly after the discovery of neuroleptic-induced supersensitivity of
striatal D 2 receptors it was proposed that dyskinetic movements result from the
interaction of endogenous dopamine with th e supe rs e nsitive D 2 rece p to rs
(28,29). Recent findings, however, have called this th eory into quest ion (30).
First, receptor supersensitivity can develop after a single ad m in istration of
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neuroleptics whereas d yskinetic symptoms a r ise only afte r prol onged adm inistration. Second, receptor supersensiti vit y d evelops in all su bjects tested, while
TD d evel ops sporadicall y. Third, receptor sup e rsens it ivity remains reversible
upon withdrawal of neuroleptics while TD ma y p e rsist inde fin itel y. Finally,
detailed post-mortem studies have fail ed to find a n association be tween st riatal
D2 receptor densit y a nd a prior history of T D (3 1). D 2 rec eptor supersensitivity,
th erefore , is probably not m ech an isti call y r elated to TD. Receptor su persensitivity may h ow e ve r be seen as a step in th e ca scade of events wh ich u ltimately
results in th e expression of d yskinetic sym p to ms .
Depolarization Inactivation

In ad d itio n to th eir beh avi oral a nd b ioch em ica l effects, neuro leptics have
been sh own to directl y affect th e fir ing patterns o f d opaminergic neurons in the
A9 a nd Al 0 midbrain nuclei, whi ch originate in the nigrostriat al a nd rneso limbic /m esocortical pathwa ys respecti vel y. Block ade of d opam inerg ic transmission
d epolari zes neurons in b oth th e A 9 and Al 0 nucle i, leadin g to an ac u te increase
in t heir firin g rate (3 2). Following chron ic neu rolept ic-induced depolarization,
howe ver, th ese n eurons grad ua lly lose their coor d inate d pa ttern of firing and
over tim e become co m p lete ly quiescent. Direct ad m in ist ra tio n of -y-am in o b utyri c ac id (G A BA) , a n in h ib ito ry transmi tter, ca n resto re activity to these
in act ivated neurons su ggesting th at th e ir in acti vati on is due to c h ron ic depolarizat ion (33). Ne u roleptic-ind uced depol arization of A l 0 neu rons is thought to
underlie the a ntipsychot ic effec ts of neurol eptics a nd p ossibl y th e ir behavioral
side e ffec ts whil e d oplarization inacti vation o f A 9 neu rons ma y be the first step
in a seq uence of even ts leadin g to T D (3 4). In this theory (35), it is h ypo th esized
that block ade o f po sts yn aptic striata l d opamine receptors lead s to a decrease in
the ac tivi ty of th e normall y inhibitory GA BA- med iate d st riatonigral feedback
pa t hw ay whi ch lead s to a depol arizati on of A9 n eu rons a nd an ac u te in crease of
st r ia ta l dopamine rel ease . Following p rolonged d opaminergi c block ad e , howe ve r, t he A9 neu rons become in capable of sus ta in ing the in creased firing rate
a nd become grad ua lly inacti ve leadin g to a decline in striatal d opamine release .
As lon g as th e st r ia to n igral G ABAe r gic ne u rons r emain intact, th e process
remains re versible . Dopamin e r g ic d enerva tion of th e GA BAergic ne uro ns,
howe ver, app ea rs to place an ad a p tive st ress upon them wh ich over t ime may
facilitate th eir d egene ration . Degene rati o n of GABAergi c str iato n igra l neu r o ns
ha s been implicat ed in th e pa thoph ysiol o gy of Hunti ngton 's chorea (10) and
Wil so n's di sease , co ndi tio ns wh ich p resent wit h dys kinet ic symptoms clinically
ind isti n guis hab le fro m th ose o f T D, a nd so ma y be t he fina l co m mon pathway
fo r the ge nerat io n o f d yskinetic movements. Ex peri men ta l destruc tion of the
str ia to n igra l path wa y in anim als leads to d epolari zat ion inacti va tion in A9 and to
the d e vel opment of d ysk in etic movem e nts (36). Cebus monke ys who are exposed
to neurolep tics over a peri od of years can dev elop d ysk in esias which closely
resem b le th ose of T D (3 7). Mo nk e ys who d e velop d ysk in esias ha ve bee n shown
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to have significantly lower levels of GABA in the substantia nigra th an mon ke ys
who do not (38) suggesting that a failure of GABAergic neurons to adapt to
functional dopaminergic denervation may be etiologicall y relat ed to th e d e ve lopment of d yskinesias. Human post-mortem studies o f sch izo p h re nics ha ve
likewise demonstrated a decreased striatal GABA lev el in subjects with a prior
history of TD versus those without (31). 0 differences in dopamine rece p to r
numbers were found in these patients. These findings suggest th at while
depolarization inactivation of A9 neurons does not directl y underlie d yski ne tic
movements. It may be the first of a cascade of events whi ch ultimatel y resul ts in
TD . Agents which do not induce depolarization ina ctivation of A 9 neu rons,
therefore, should be relatively without dyskinetogenic potential.
Administration of the traditional neuroleptics ch lo r p ro ma zine, hal ope r idol and fluphenazine has been shown to lead to an ac ute in crease in th e firi ng
rate of neurons in both A9 and A I 0 followed by a sustained depolari zati on
inact iva tio n of these neurons (39-41). By contrast, clozapine (33,39,40), thi oridazine (39), sulpiride (39) and molindone (39) have been shown not to induce
depolarization inactivation in A9. Acute administration of th ese agents in creases
the firing rate of neurons in Al 0 but not in A9 while th eir ch ron ic ad m in ist ration leads to a decrease in the firing rates of neurons onl y in Al O. Clozapine an d
molindone (41) have also been shown to reverse th e inhibition o f firin g rates
induced by ch ro n ic haloperidol at the dosages used in th ese stu d ies. Clozapine ,
thioridazine, sulpiride and molindone therefore , ap pea r not to inhibit nigrostriatal dopaminergic transmission and so ma y be less likel y than tradi tion a l
agents to induce TD. l-Sulpiride, the "active" isomer o f su lp ir ide, has bee n
shown to induce depolarization inactivation of A9 wh en administered o n its own
whereas d-sulpiride, the " inactive " isomer, has no e ffec t (33). Fo r su lp iride,
therefore , at ypicality may depend upon administering racemate l-sul p ir id e
which is the clinicall y available form o f the d rug.
Possible Mechanisms ofN eu roleptic Atypicality

The exact mechanism b y which atypical neuroleptics spare th e nigrostriat al
system remains a question of intense debate. One common a b ility of all putat ive
atypicals is to selectively increase presynaptic dopamine release in th e str iatum.
Presynaptic dopamine synthesis and release can be assayed either by mea suri ng
the activity of tyrosine hydroxylase, the rate limiting e n zyme responsibl e for
dopamine synthesis, or by directly measuring the levels of dopamine metabolites. Using these assays, it has been found that c1ozapine, thioridazine, su lp iride
and molindone all increase dopamine synthesis and release in the striatum but
that they differ in the mechanism by which they do so. Clozapine and thiorid azine have been found to stimulate tyrosine h ydrox ylase activity via nonhaloperidol sensitive receptors (43) and to increase DA metabolite lev el s via a
transsynaptic mechanism (44). Molindone (44) and sulpiride (45 ), co nverse ly,
appear to operate via a homosynaptic mechanism . The at ypical effec ts of
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clo zap ine and thioridazine , th erefore , are probably mediated via t hei r actions on
th e non-dopamin ergic brain systems whi ch r egulate dopaminergic transmission
whil e th e at ypical effec ts of molindone a nd su lp ir ide are most p roba b ly mediated
via their direct e ffec ts o n th e dopaminergic te rm in als.
Clozapine and to a lesser ex te n t thiorida zin e ha ve been shown to have
relativel y low p oten cies of ac tion a t brain O 2 receptors a nd rel a ti vel y high
potencies at D. dopaminergic receptors, at adrenergic recepto rs, a t m usca r in ic
cholinergic receptors and at serotonergic receptors (46,47). It rema ins unclear
whi ch if any of these rec eptors mediates the atypi cal effec ts of clozapine and
thioridazin e . Mo st attention has b een foc used upon a n t i-cho linergic and antiadrenergic effec ts (48, 4 9) . More recently it has been suggested t ha t the a ntiser ito ne rgic potency of clo za p ine may cont r ib u te to its a ty p ica lity as we ll. In on e
study, LSD , a sero to ne r gic ag o n ist , potentiated the h yperact ivity induced by th e
dopamin ergi c ag ent apomorphine. Clozapine but not h alope ridol or su ip iride
inhibited the LSD-induced potentiation of apomorph in e h yperacti vity (50)
suggesting that clozapine has a distin ct effec t o n brain serotonergic systems
whe n compared with other neuroleptics. Thioridazine was no t ex plicitly te sted
in this paradi gm. Striatum (5 I ) and su bs ta ntia ni gra (32) receive in nervation
from brain se r otoner g ic systems suggestin g that se roto ni n may pla y a modulatory role in nigrostriatal syste m fu nctio n in g. The m ech an ism by wh ich clozapine 's anti-serotonergic e ffec ts might result in a decreased d yskine tic po te nti al,
however, remains to be determined .
By co n t rast to clo za p ine and thioridazine , molindone a nd su lp iride bind
ex treme ly weakl y to OJ receptors, to muscarinic c ho linergic receptors, to
ad rener g ic receptors a nd to se roto nergic receptors (4 6, 4 7). Both mol indo ne and
su lp ir ide, however, bind potently to a class of d opam ine receptors called
dopamin e autoreceptors (OARs). OARs respond directl y to pre-syn a p tically
rel eased dopamin e and serve to inhibit furth er dopamin e release. Block ad e of
this negative feedback system effec t ive ly in creases th e rate o f p re-syn ap tic
dopamine synthesis and rel ease (52 ). Low d o se apomorphine «0.4 mg/kg)
se lec tive ly st im u la tes OARs (5 3). Usin g ap o mor p h ine to assess DAR functionin g , it has been found that molindone inhibits DARs 2-4 ti mes m ore pote n tl y
than post-synaptic receptors. In th e d ose ra nge of 1- 3 mg/kg , mo lind o ne
preferentially inhibits OARs (22,54-56). Sulpiride h as a lso been shown to
preferentially inhibit OARs, at doses up to 10 mg/kg (2 1,5 3). C loza pi ne and
thioridazine, as opposed to molindone and sulpiride, appear to a ntagonize
DAR-mediated activities extremel y weakly (5 3, 54) . OARs h ave bee n shown to
regulate dopamine release in the nigrostriatal system (59). Agen ts which act
preferentiall y on OARs, therefore , would be e xpecte d not to inhibit a nd possibly
to e n h a nc e dopaminergic neurotran smi ssion in the striatum. Su ch a n effect
could underlie th e atypical effects of molindone a nd su lp ir ide in a n ima l models
of TO. It sho u ld be noted, however, that at high doses molindon e a nd su lp ir ide
ca n effectivel y block postsynaptic dopamine rec eptors. At high doses, therefore ,
these agents might be expected to behave sim ila rly to tradition al neur ol eptics.
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A Model f or N egative Symptom s

In addition to regulating nigrostriatal functioning , OAR s regu late mesolimbic dopaminergic transmission (52 ,60,6 I) . Stimulation o f post syn aptic dopamine receptors with amphetamine or high dose apomorphine has been shown to
induce motor hyperactivity which is mediated via th e mesolimbic system . Low
dose apomorphine , conversely, binds preferentially to OARs, leadi ng to
decreased mesolimbic dopamine release and a charac te r ist ic syndrome of
hypomotility and sedation in rodents (53) . Neither clo zap ine nor thio ri d azine
reverses the h ypomotility induced by low dose apomorphine (53). T hese agents ,
therefore, appear to have littl e ability to reverse mesolimbic d opaminerg ic
blockade. Conversely su lpiride has been shown to inhibit apomorphine-induced
h ypom otility (53) suggesting th at it may not induce net dopaminergic underactivity in the mesolimbi c system when administered alone. While th e effec t of
molindone on h ypo mot ility has not been explicitly tested, mol indone ha s been
shown to inh ibi t the effects of lo w dose apomorphine on dopamin e re lease
(54,56) and so wo uld be expected to share su lpiride's behavioral effec ts.
T he relationship between apomorphine-induced h ypom otility and sch izophrenic symptomatology remains to be determined. In one stu dy (6 2), however ,
it was shown that apomorphine-induced hypomotility is accompan ied by a
reward deficit in rats. Untreated rats show an a b ility to increase th eir ra te of bar
pressing when they are sh ifted from a sched u le in whi ch th ey a re re warded with
a food pellet for each response to one in whi ch they are r ewarded fo r o nly every
fourth response. After three sessions untreated rats are a b le to o btai n t he same
number of pellets as before th e shift in reward sch edule. Rats pretrea ted with
low dose apomorphine , however, fail to sig nifica nt ly a lter t heir ra te o f
responding following th e sh ift in reward sch edule. Sin ce th e rat s rema in
ph ysicall y capable of increasing their responding rat e , th is fa ilu re o f responding
ma y represent a d ecreased responsiveness to sec o nda ry reinfo rcers. It was
proposed that this decreased re sponsiveness might represent a mod el for
depressive-like negative schizophrenic sym p to ms such as anh edonia and e motional withdrawal. Sulpiride co mp lete ly reverses th e reward d eficit induced by
a po mo r p h ine . Thiorida zin e, haloperidol , chlorproma zin e and fluph enazine b y
contrast fail to reverse the apornophine-induced r eward d eficit a t any dose.
Molindone has not been explicitly tested in this paradigm.
In man, the mesolimbic system appears to regulate behavioral ac tivity and
mood. Low dose apomorphine produces sedation and sleep and ma y precipitate
severe depression (63 ). Underactivity of th e mesolimbic syste m ap pears to be
involved in the psychomotor retardation and poor e nv iro nmenta l react ivity seen
in patients with Parkinson's dis ease (9) and e nd oge nous d epr ession (64,65).
Furthermore, based upon animal models , it has been po stulated th at OARh ypersensitivity, leading to diminish ed mesolimbic dopam ine rel ease , might be
e t io log ic in some forms of retarded depression (66). T he role of OAR s in
humans, th erefore, ma y be simi lar to th eir rol e in rodents. T he a bil ity o f
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molindone and sulpiride to preferentially block OARs m ight predi ct tha t these
agents could preferentiall y treat th e d epressive-like negati ve sym p toms including psychomotor retardation and e motio na l withdraw al.
CLINICAL STUDIES

While the basi c models of T O a n d negati ve sym p to ms suggest th at
c1ozapine, thioridazine, su lp ir id e and molindon e ma y produce a ty pica l clinical
effe cts, ultimate co n fir m a t io n or refutation o f these p redict ions ca n o nl y be
o b ta ined from detail ed clinical stud ies . Sin ce TO gen e rall y de vel ops 1- 2 years
a fte r the initiation of neuroleptic therapy a nd occu rs only in a mi nori ty o f
subjects (66), definitive comparison of the relative d yskinetogeni c pote ntia l o f
neuroleptics requires long-term longitudin al stud ies of fir st break sc h izophreni c
pati ents spanning se ve ra l yea rs a nd in vol vin g large numbers of su bjects . O f th e
four neuroleptics which show atypical effects in animal model s, o n ly cloza p ine
has been su bj ecte d to su fficie n t study to suggest th at it has sig ni fica nt ly lower
d yskinetogenic potential than traditional agents. In o ne stu dy of 21 6 psyc hiatric
patients treated with clozapine as sole neuroleptic'for up to 12 yea rs no cases of
TO were reported (67 ). Other studies have sim ila r ly show n a d ecreased d yskinetic potential for clozapine (6 8) . Th ioridazin e , su lp ir ide an d mol ind o ne , by
contrast , ha ve not been subject ed to suffici ently lon g-t e rm stu d ies to a llow an
estimation of th eir d yskinetic potential ve rs us traditional agen ts.
In th e absence of long-term longitudinal stud ies of sch izophrenic patients,
"masking" paradigms have been used to try to study th e rel at ive dys kinetogenic
potentials of neuroleptic agents. In this approach, su bjects are ch osen wh o ha ve
developed persistent withdrawal exacerbated TO. Th ese subjects a re ass igned to
different neuroleptic regimens a n d th e potency wit h wh ich th ese agents mask
dyskineti c symptoms is determined. Based upon a n ima l studies (3 7,69, 70), it ha s
been proposed that those agents which a re least potent in maskin g dys kinet ic
sym p to ms sho u ld be lea st likely to induce de novo TO . In a clo sel y rela ted
paradigm , subjects with preexisting TO are e xp osed to neuroleptics and the
post- vs. pre-exposure severity of TO is determined . Studies usin g th ese
paradigms have been conducted with haloperidol a nd with th e p roposed
atypicals clo zap ine, thioridazin e and molindone . Acti ve treatm ent wit h halope r idol has been shown to potently mask d yskineti c sym p to ms . Subsequent withdrawal of haloperidol leads to a rebound worsening of d ysk in eti c sym ptoms
sugge st ing th at a progression o f the underl ying process h as occured (69-76) .
Clozapin e, by contrast , has been sh o wn to have no sign ifica n t a n tidys kine tic
effects and withdrawal of clozapine does not lead to rebound worsenin g (70, 7 1).
Thioridazine (70 ) and molindone (72) also mask d yskineti c sym ptoms less
potently than haloperidol does. Th ese agents, however, do produce a significant
degree of masking and therefore cannot be co nsid e red fr ee of d yskinetogenic
potential. While sulpiride has been shown in human s to ha ve so me a b ility to
mask d yskineti c symptom s (7 3 ,74) , its poten cy h as not been directl y co mpared
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e ither to traditional neuroleptics or to ot her a typ icals . In Cebus monke ys with
persistent n euroleptic-induced o ro fac ia l d yskinesias su lpiride has been shown to
mask d yskinetic movements to a lesse r d egree th a n either ha loperidol or
fluph enazin e (75). In addition to c1o zapine , thioridazin e (70) and sul piride (75)
d o not induce r ebound worsening of TO. Addit ionall y, clozapi ne and thioridazine ha ve also been found not to induce r ebound wo rsen ing in Cebus monke ys
with persistent d yskinesia s (76) . Molindone has not b ee n d irect ly tested in th e
r ebound worsening paradi gm . T hese stud ies su pport the basic p rediction that
c1ozapine, thioridazin e, su lp ir ide an d molindone h a ve re latively decreased
d yskinetogenic potential wh en co m pared with tradition al agents. Only c1ozapine, however, appears inacti ve in th ese paradigms, suggesti ng th a t the other
three agents might st ill ha ve sign ifica n t although d ecreased r isks of associated
T O. Furthermore, although thioridazine does not p roduce re boun d wo rsenin g
of TO in monkeys, two of its metabolites, mesoridazin e a nd su lfo r idazine, have
been shown to induce rebound worsening while a third me tabol ite, thiori dazine
ring sulfoxide, does not (69) . Indi vidual metaboli sm ma y the re fo re affect
wh ether thioridazine and possibl y o t her neuroleptics ha ve d ecreased d ysk ine to gen ic potential in an y giv en su bject.
Negative symptom s have a lso proven diffi cult to study clinica lly. No
d efinitive stud ies ha ve been co nd uc ted wh ich e it her sup port or re fu te the
su ggest io n that sulpiride and molindone sh o u ld be more efficacio us than other
neurol eptics in treating negati ve sym p to ms . Difficulties arise because negative
sym p to ms ha ve proven diffi cult both to define a nd opera t io na lize. In the last few
yea rs, how e ver, phenomenologi cal stud ies ha ve d em onst ra ted that d e p ressivelike negative symptoms (e .g . fatigue , blunted affect a nd loss of inte rest) constitute a cluster of symptoms whi ch a re d istinct from e it her positive o r hebephrenic-lik e negati ve sym p to ms (77, 78). T he se pa rate clus te r ing of th ese symptoms
suggests that they ma y be e tio logically di stinct fr om o ther sym ptoms of schizophrenia and may possibl y be mediated by different brain path wa ys. Ope ra tio na lized cr ite r ia for negative sym p to ms ha ve b een proposed o n ly within th e last few
yea rs (79 ,80). Since no stud ies have di rectl y co m pa red neuroleptics usin g well
validated negative symptom sca les, no firm co ncl us io ns ca n be drawn concerning
the relative effectiveness of typi cal and at ypical neurol eptics in treating nega tive
symptoms. Prelim inary conclusions can be drawn , howe ver, fr om medica t io n
tria ls which utilized the Brief Psychiatric Rating Scal e (BPRS) (8 I) . Three BP RS
items, emotional withdrawal, blunted affect, and motor retardation h ave bee n
found to correlate with negative sym p toms scores but not with positiv e symptoms suggesting that they might be useful post-hoc measures o f negati ve
symptomatology (77 ,82) . These symptoms are commonly co m b ined to for m t he
withdrawa l/retardation su bsea Ie (8 I) .
In reviewing three st ud ies (83-85) which com pa red clozap ine eit her to
ba seline or to reference neuroleptic (chlorpromazine or haloperidol), clozapine
sig n ifica n tly improved symptoms of withdrawal and retardation in two of the
three. In none of these studies, however, were th e differen ces sig n ifica nt versus
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a reference neuroleptic. In a fourth st udy, clozap ine fa iled to im prove an y o f th e
BPRS negative sym p to ms (86). Pe rh aps most indicat ive of th e effects of clo zapin e are the results of a large multicenter Europea n study (87) in whi ch
cloza p ine was compared wit h three re ference neurol eptics. While clozapine was
effec tive ov e ra ll in treating BPRS negati ve symptoms, no clea r d iffe re ntial effect
was observed. In one subs t udy, clozap ine was superior to ch lorpromazine in th e
treatment of with d rawal/retard a t io n . The differential e ffect, however, was less
th an for h yperacti vit y a nd co re symptoms, howe ver, suggest ing tha t clozapine's
super io r ity was global rather than rest ri ct ed to negative sym p toms .
Thioridazine and its acti ve metabolite meso ridazin e ha ve simi larly been
co m pa red with refe rence n euroleptics in a number of stud ies. In three studies
(88 -90), thioridazin e has been sho wn to be relativel y in effecti ve in a meliorating
e mo t io nal withdrawal and psychomotor retardation. Mesoridazin e , its active
metabolite, has been shown to be somewhat more effect ive in the t reatm e n t of
negative symptoms (89 -93) possibl y because it is less se da ti ng. Meso r id azine
also , however, has been found not to be sig n ifica n t ly better than refere nce in
treating negative symptoms. Moreover, in on e st udy in whi ch a ll BPRS symptoms improved significantl y following treatment with mesoridazine , bl u n ted
affect and e mo tio na l withdrawal sh o wed th e least impr ov emen t (93) .
Sulpiride ha s been relatively poorl y stu d ied in trials wh ich e mp loy the
BPRS. In three such studies (94- 96), sulpiride was found to consistently
am eliorate e m ot io na l withdraw al, motor r etardation a nd e mot iona l b lunting
along with the subscal e anergia , although in non e of th ese stud ies was su lpiride
sign ifica n t ly superior to th e reference neuroleptic (ha lope r idol). H owe ve r , in
o ne study whi ch used the Compreh ensive Psych opath ol ogi cal Ratin g Sca le
(C PRS) to compare su ipi ride ve rs us cho lo r p r o mazine (9 7), su lp ir ide was found
to be sign ifica n tly super io r to c h lorp rom az ine in th e trea tm ent of autistic
sym p to ms . These symptoms whi ch consisted of inability to fee l, lassitud e ,
withdrawal , reduced speech and slow ness of movement are a na logous to BPRS
d efined negative sym p to ms but have not been directl y va lidate d aga ins t t hem .
While sulpiride a n d chlorpromazin e both produced sign ifica nt impr oveme nt in
global symptomatology and in positive sym p toms, su lp ir ide sig n ificant ly
decreased autistic symptoms whereas chlorpromazine did not. O f inte rest ,
su lp ir id e-ind uced improvement in negative symptoms was found to be inv e r se ly
cor re la ted with sulpiride drug concentration such that those subj ect s with the
highest serum sulpiride concentrations were found to have th e lea st impr o vement in negative symptoms. Moreover, no significant correlation was fo und
between serum levels of eit he r sulpiride (or c h lo r p r o maz ine) and positi ve
sch izop h re n ic symptoms. Since the dosage of sulpiride used in the last study (800
mg/day) was significantl y less than the dosages in the three stud ies e m p loying
th e BPRS (1200-1600 mg/d mean final dosage) th e differences in o utcome
might be related to the dosage differences. Two other uncontroll ed studies ha ve
al so suggested that sulpiride may have anti-autistic effec ts a t dosages of 800 (98)
and 600- I 200 (99) mg/day. Th ese stud ies, therefore , suggest th at lo w dose
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su lp ir ide may have rela t ive ly im proved efficacy in treati ng negative symptom s
a lt houg h at high doses th is diffe ren t ial effect may be lost.
O f 16 clinical tria ls with molindone, 7 have compared it to a referen ce
neurolep tic using the BPRS (100- 106) . O f t hese, six demon strated improvement either in the items; emotional withdrawal, motor retardation a nd blunted
affect o r in the withdrawa l/re tardation subscale whic h encompasses t hese items.
O f th e fo ur studies whic h m easu red the wit hdrawal/retardation subscal e explicitl y (103- 106), all fo ur d emonstrated a sig nificant response of these symptoms to
molindone but no t to refere nce neuroleptic. In th ree of these stu d ies, th e
p referential effects of mol indone on negative symptoms were statisticall y sig nificant. These studies support the prediction based upon animal models th at
mol in done may be superior to traditiona l neuroleptics in th e treatment of
negative symptoms.
T HE RA PEUT IC I MPLI C AT IO N S

T hese clinica l studies support the animal model-based predictions th at
clozapine, th ioridazine, mol ind o ne , and su lpiride may have relativel y d ecreased
d yskinetogenic potential compared with traditional agents. Onl y clo zapine ,
however, appears completely free of associated TO. Of the four at ypical ag ents,
on ly two , th ioridazine and mo lindone, are currentl y available for nonex per imenta l use in the U .S. T hese age nts appear to differ in the me chanism o f
t heir atyp ica lity and in th e ir cl inica l effects. T hioridazine which is a re latively
sedating ne urolept ic with no apparent specific efficacy in treating negati ve
sym ptoms appears to be more clozapi ne-like in its mechanism of atypi cality.
Molindone, conversely, mo re closely resemb les the proposed at ypi cal agen t
sulpiri de and a ppears to prod uce atypical clin ica l effects b y virtue of its ability to
se lective ly blo ck presy na pt ic d opami ne autoreceptors (OARs). Molindon e , like
su lp ir ide, has been show n to be r ela tivel y mo re effective in treating negative
sym ptoms of sch izophrenia t ha n tradit io nal neuroleptics. A t heoretical concern
wit h mol indo ne is that, like sulpi ri de , it may lose its atypicality at high dosages.
In an imal studies, mol indone has bee n shown to lose some degree of atypicality
at dosages over 3 mg/kg (24,25). W hether a similar therapeutic window ex ists
clinically remains to be d e te r m ined .
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